` LXGTF (Lexington Biosciences Holdings Corp) vs S&P 500 Comparison - Alpha Spread

L
LXGTF
vs
S&P 500

Over the past 12 months, LXGTF has underperformed S&P 500, delivering a return of 0% compared to the S&P 500's +15% growth.

Stocks Performance
LXGTF vs S&P 500

Loading
LXGTF
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
LXGTF vs S&P 500

Loading
LXGTF
S&P 500
Difference
www.alphaspread.com

Performance By Year
LXGTF vs S&P 500

Loading
LXGTF
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Lexington Biosciences Holdings Corp vs Peers

S&P 500
LXGTF
BDX
DXCM
4543
PODD
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Lexington Biosciences Holdings Corp
Glance View

Market Cap
38 USD
Industry
N/A

Lexington Biosciences, Inc. is a medical device company, which engages in the research and development of non-diagnostic devices. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2017-06-01. The device measures the function of the endothelium, the cells that line all arteries and are critical to the prevention of atherosclerosis, heart attacks and stroke. The firm is in the final stages of releasing the developed product for clinical studies. The firm's goal is to make HeartSentry accurate, quick, and cost effective so it can become the standard of care for cardiologists, general practitioners, and ultimately patients for first line evaluation of a person’s cardiovascular health.

LXGTF Intrinsic Value
Not Available
L
Back to Top